Thyroid Cancer Diagnosis
Thyroid Cancer Diagnosis
Diagnosis is made with an ultrasound and a needle, not an operation. Cytology classifies the nodule, staging adds the age rule, and molecular testing on the same specimen decides what happens if the disease returns.
Ultrasound: where the assessment starts
Ultrasound is the first and most informative test, and it is done before any decision about a needle. It answers four things: how big the nodule is, what it is made of, whether it has features associated with malignancy, and whether the lymph nodes beside the thyroid look normal. Neck nodes matter as much as the nodule itself, because a normal-looking primary with an abnormal node is still a nodal disease.
The features are graded rather than judged one at a time. A solid hypoechoic nodule with irregular margins, a taller-than-wide shape and microcalcification sits in the highest category; a spongiform nodule or a purely cystic one sits in the lowest. That graded score — TI-RADS — sets the size threshold for biopsy, which is why the biopsy decision is reproducible between centres rather than a matter of opinion.
Fine-needle aspiration: what it can and cannot do
A fine-needle aspiration takes cells through a thin needle, usually with ultrasound guidance. It is quick, it does not require anaesthesia, and it does not seed the tumour along the needle track — that concern is a myth, and the risk of it happening is negligible.
What it cannot do is answer a structural question. Cytology sees cells; it does not see whether a capsule has been breached. That is the reason follicular carcinoma cannot be diagnosed on a needle sample: a benign follicular adenoma and a follicular carcinoma can contain identical-looking cells, and the difference lies in whether the tumour has invaded its capsule or vessels, which requires the whole nodule. This limitation is well understood, and it is the reason a proportion of nodules go to diagnostic surgery rather than to further tests.
Reading the cytology report
Aspirates are reported in six Bethesda categories, and each carries a different probability of malignancy and a different next step:
- Bethesda I — non-diagnostic. Not enough cells. Usually repeated, sometimes with a larger needle.
- Bethesda II — benign. The great majority. Followed on ultrasound rather than operated on.
- Bethesda III — atypia of undetermined significance. The largest indeterminate group, and the one where molecular testing changes management most.
- Bethesda IV — follicular neoplasm. Cells suggest a follicular lesion; the diagnosis cannot be completed without the whole nodule, so surgery is often both diagnosis and treatment.
- Bethesda V — suspicious for malignancy. Usually operated on.
- Bethesda VI — malignant. Diagnostic, and surgery follows.
If your report says Bethesda III or IV, the useful question is not what the category is called but what can be done with the specimen that already exists. In many cases the answer is molecular testing, which can move the nodule into a benign or suspicious group without another needle.
Molecular testing on the same specimen
Molecular testing is performed on the aspirate that has already been taken, or on the resected tissue if surgery has happened. It has two separate uses, and they are often confused.
The diagnostic use is in indeterminate nodules. A mutation with a high probability of malignancy — BRAF V600E above all — makes a Bethesda III or IV nodule much more likely to be cancer, and a benign-expression classifier can move a nodule towards surveillance. Neither test replaces the pathologist; both sharpen a decision that would otherwise be a guess. The prognostic and therapeutic use is in disease that has already been diagnosed: BRAF, RAS, TERT and RET results feed into how complete the first operation should be, and into which targeted drug becomes available if the disease advances and stops taking up iodine.
Staging, and why age is part of it
Staging answers two questions for differentiated thyroid cancer — how far the tumour has grown beyond the gland, and whether it has reached distant organs — but the AJCC system adds a third variable that no other common cancer uses: the patient's age at diagnosis, with the dividing line at 55.
Under 55, only Stage I and Stage II exist. Stage I means any tumour with or without neck nodes and no distant spread; Stage II means distant spread is present. At or over 55, the size of the tumour, its extension into structures outside the thyroid and the involvement of nodes all count, and Stages III and IV become possible. This is why the stage should never be read without the age beside it — and why a young patient with involved nodes is often described more reassuringly than the ultrasound report alone would suggest.
Arranging the work-up from abroad
Most of a thyroid work-up can be done from your own country, and much of the value of a review is in telling you which parts are genuinely needed. What the team needs to see is not a summary but the material: the ultrasound images rather than the radiologist's paragraph, the cytology slides or block if a diagnosis is still open, and the molecular result if one has been done.
Three things commonly need to be added. A laryngoscopy documents vocal cord function before surgery, so that a pre-existing nerve weakness is not mistaken for a surgical complication afterwards. Thyroid function and antibody tests establish the baseline the hormone replacement will be built on. And a repeat ultrasound of the neck nodes by the operating team is usual practice, because nodal assessment is what decides whether a neck dissection is part of the operation.